CB1 Capital Management predicts Cannabis could disrupt the healthcare industry in a big way. The firm's Founding Partner and Chief Investment Officer Todd Harrison explains why he thinks medical marijuana will migrate from state dispensaries, to become medicine prescribed by doctors through insurance in the next decade.
Harrison says the only way the U.S. government would get their hands on the money in this market opportunity is through the FDA. "That's where we think it goes, follow the money," says Harrison.
"This is not so much a trade about commerce, as it is a trade about healthcare," said Harrison. "We think that this is going to migrate towards medicine." One of CB1 Capital Management's holdings GW Pharmaceuticals is up 30 percent over the past three months. Harrison expects this company to publish research showing the efficacy of cannabis treatment this summer.
Jasmine Sun on unregulated peptides moving from fringe biohacking to Silicon Valley mainstream, promising healing, focus, and optimization with little oversight
For Trump, markets matter more than polls. Luke Broadwater, White House correspondent for The New York Times, examines how Wall Street guides decisions.
As political and economic uncertainty rises, Americans are seeking second passports and golden visas. Latitude Group’s CEO explains what’s driving the surge.
As AI and electrification drive record power demand, nuclear energy returns to the spotlight. Lightbridge CEO explains how advanced fuel could reshape the grid.
Shark Tank’s Kevin O’Leary breaks down his Hollywood debut, Marty Supreme’s $100M box office run, Oscar buzz, and what business taught him about movies.
